NPCE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
22.8M
+3.4%
22.1M
-17.0%
26.6M
-2.8%
27.4M
+40.3%
19.5M
Cost of Revenue
3.9M
-2.5%
4.0M
-33.1%
6.0M
-2.8%
6.2M
+88.1%
3.3M
Gross Profit
18.9M
+4.8%
18.0M
-12.3%
20.6M
-2.8%
21.2M
+30.6%
16.2M
Operating Expenses
24.0M
+1.8%
23.6M
+5.7%
22.3M
-6.0%
23.8M
-2.6%
24.4M
R&D
6.9M
-4.0%
7.2M
+2.3%
7.0M
+6.9%
6.6M
-3.9%
6.8M
SG&A
17.2M
+4.4%
16.4M
+7.2%
15.3M
-10.9%
17.2M
-2.1%
17.6M
Operating Income
-5143000
+7.6%
-5568000
-215.1%
-1767000
+32.0%
-2600000
+68.3%
-8189000
EBITDA
-5077000
+7.8%
-5508000
-226.5%
-1687000
+33.7%
-2546000
+68.7%
-8134000
Net Income
-6200000
+7.3%
-6689000
-145.1%
-2729000
+21.9%
-3496000
+59.6%
-8651000
EPS (Basic)
$-0.18
+10.0%
$-0.20
-150.0%
$-0.08
+27.3%
$-0.11
+57.7%
$-0.26
EPS (Diluted)
$-0.18
+10.0%
$-0.20
-150.0%
$-0.08
+27.3%
$-0.11
+57.7%
$-0.26
Shares (Diluted)
34.1M
+1.1%
33.7M
+0.9%
33.4M
+0.8%
33.1M
+0.8%
32.9M
Neuropace (NPCE) โ€” Financials